Rosiglitazone increases matrix production and quenches inflammation: Studies in human cells

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 3, 2008, Pages 197-204

  Solini, Anna ^a   Santini, Eleonora ^a   Madec, Stephanie ^a   Nannipieri, Monica ^a   Bonotti, Alessandra ^b   Cuccato, Sabina ^a   Ferrannini, Ele ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

ExtraceUular matrix; Inflammation; Rosiglitazone; Type 2 diabetes

Indexed keywords

FIBRONECTIN; INSULIN; INTERLEUKIN 6; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PHORBOL 13 ACETATE 12 MYRISTATE; ROSIGLITAZONE; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

CELL CULTURE TECHNIQUES; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-6; LAMININ; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 40749086747     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.781     Document Type: Article

References (44)

1. Libby P, Shi GP. Mast cells as mediators and modulators of atherogenesis. Circulation 2007; 115: 2471-2473.
2. Sanz J, Moreno PR, Fuster V. Update on advances in atherothrombosis. Nat Clin Pract Cardiovasc Med 2007; 4: 78-89.
3. Viles-Gonzales JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. Curr Mol Med 2006; 6: 489-499.
4. Hinz B, Phan SH, Thannickal VJ, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-1816.
5. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 2007; 100: 1546-1555.
6. De jager J, Dekker JM, Kooy A, et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol 2006; 26: 1086-1093.
7. Natali A, Toschi E, Baldeweg S, et al. Glustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006; 55: 1133-1140.
8. Castillo G, Brun RP, Rosenfield JK, et al. An adipogenic cofactor bound by the differentiation domain of PPAR)γ. EMBO J 1999; 18: 3676-3687.
9. Rival Y, Beneteau N, Taillandier T, et al. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002; 435: 143-151.
10. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703-710.
11. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763.
12. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
13. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704-711.
14. Pugliese G, Pricci F, Locuratolo N, et al. Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions: relation to glucose-enhanced extracellular matrix production. Diabetologia 1996; 39: 774-784.
15. Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1146-L1153.
16. Zheng F, Fornoni A, Elliot SJ, et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002; 282: F639-F648.
17. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, Tejerina T. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes 2005; 54: 811-817.
18. Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002; 87: 385-392.
19. Bhagavathula N, Nerusu KC, Lal A, et al. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004; 122: 130-139.
20. O'Leary R, Ponnambalam S, Wood EJ. Pioglitazone-induced myofibroblast cell death: implications for cutaneous scarring. Br J Dermatol 2003; 149: 665-667.
21. Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005; 327: 460-467.
22. Lindschau C, Quass P, Menne J, et al. Glucose-induced TGF-beta1 and TGF-beta receptor-1 expression in vascular smooth muscle cells is mediated by protein kinase C-alpha. Hypertension 2003; 42: 335-341.
23. Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal-regulated kinase and protein kinase Cdelta activities in human mesangial cells. J Am Soc Nephrol 2004; 15: 2032-2041.
24. Hammes HP. Pathophysiological mechanisms of diabetic angiopathy. J Diabetes Complicat 2003; 17(Suppl 2): 16-19.
25. Hattori Y, Akimoto K, Kasai K. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun 2000; 273: 1144-1149.
26. Weigert C, Brodbeck K, Bierhaus A, Haring HU, Schleicher ED. c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. Biochem Biophys Res Commun 2003; 304: 301-307.
27. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferator-activated receptor y antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002; 16: 2628-2644.
28. McLennan SV, Martell SKY, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-2618.
29. Yevdokimova NY, Podpryatov SE. Hyaluronic acid production and CD44 expression in cultured dermal fibroblasts of patients with non-insulin-dependent diabetes mellitus with and without chronic ulcers on the lower extremity. Wound Repair Regen 2005; 13: 181-188.
30. Schaefer T, Roux M, Stuhlsatz HW, et al. Glycosaminoglycans modulate cell-matrix interactions of human fibroblasts and endothelial cells in vitro. J Cell Sci 1996; 109: 479-488.
31. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005; 161: 113-122.
32. Xiong Z, Huang H, Li J, Guan Y, Wang H. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells. Ren Fail 2004; 26: 497-505.
33. Shah RD, Gonzales F, Golez E, et al. The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha-and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Cell Physiol Biochem 2005; 15: 41-50.
34. Desmet C, Warzee B, Gosset P, et al. Pro-inflammatory properties for thiazolidinediones. Biochem Pharmacol 2005; 69: 255-265.
35. Devaraj S, Venugopal SK, Singh U, Jalal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-alpha and -beta. Diabetes 2005; 54: 85-91.
36. Verrier E, Wang L, Wadham C, et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 2004; 94: 1515-1522.
37. Kanoh Y, Bandyopadhyay G, Sajan MP, Standaert ML, Farese RV. Thiazolidinedione treatment enhances insulin effects on protein kinase C-zeta/lambda activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki type II diabetic rats. J Biol Chem 2000; 275: 16690-16696.
38. Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R. Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Diabetes 1999; 48: 595-602.
39. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005; 5: 921-928.
40. Force T, Bonventre JV. Growth factors and mitogen-activated protein kinases. Hypertension 1998; 31: 152-161.
41. Bulavin DV, Amudson SA, Fornace AJ. p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev 2002; 12: 92-97.
42. Perng DW, Wu YC, Chang KT, et al. Leukotriene C4 induces TGF-beta1 production in airway epithelium via p38 kinase pathway. Am J Respir Cell Mol Biol 2006; 34: 101-107.
43. Hu Y, Dietrich H, Metzler B, Wick G, Xu Q. Hyperexpression and activation of extracellular signal-regulated kinases (ERK1/2) in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 18-26.
44. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001; 167: 5381-5385.